Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Colombel during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Protagonist Therapeutics, Inc.
- Envision Pharma
- Immunic
- GlaxoSmithKline
- Pfizer Inc.
- Shire
- Ferring Pharmaceuticals
- Boehringer Ingelheim Corporation
- Anapty Bio
- Boxer
- Eli Lilly and Company
- Ensho
- Merck & Co., Inc.
- Microbia Novartic
- Landos
- Alimentiv
- Tigenix
- Celgene Corporation
- Teva
- Amgen Inc.
- Sanofi
- Takeda Pharmaceuticals International GmbH
- Otsuka Pharmaceutical Co., Ltd.
- Bristol-Myers Squibb
- WEBMD Health Corp
- Integritas Communication
- Prometheus Laboratories Inc.
- AbbVie Inc.
- Sun
- Arena
- Imedex, LLC.
- Seres
- Allergan, Inc.
- Genentech, Inc.
- Janssen Pharmaceuticals, Inc.
- Union Therapeutics A/S
- Iterative Scope
- Vifor
- Galmed research
- Guide Point
- Kaleido
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Intestinal Biotech Development
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Colombel during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Protagonist Therapeutics, Inc.
- Envision Pharma
- Immunic
- GlaxoSmithKline
- Pfizer Inc.
- Shire
- Ferring Pharmaceuticals
- Boehringer Ingelheim Corporation
- Anapty Bio
- Boxer
- Eli Lilly and Company
- Ensho
- Merck & Co., Inc.
- Microbia Novartic
- Landos
- Alimentiv
- Tigenix
- Celgene Corporation
- Teva
- Amgen Inc.
- Sanofi
- Takeda Pharmaceuticals International GmbH
- Otsuka Pharmaceutical Co., Ltd.
- Bristol-Myers Squibb
- WEBMD Health Corp
- Integritas Communication
- Prometheus Laboratories Inc.
- AbbVie Inc.
- Sun
- Arena
- Imedex, LLC.
- Seres
- Allergan, Inc.
- Genentech, Inc.
- Janssen Pharmaceuticals, Inc.
- Union Therapeutics A/S
- Iterative Scope
- Vifor
- Galmed research
- Guide Point
- Kaleido
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Intestinal Biotech Development
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.